Prenetics (PRE) Stock News

Prenetics Global Limited (NASDAQ: PRE) announced that world No. 1 tennis star Aryna Sabalenka has joined IM8 Health as both global ambassador and shareholder, marking the first time a current athlete has become a shareholder in Prenetics.

IM8, a premium supplements brand co-founded by David Beckham, has achieved remarkable growth since its December 2024 launch, generating over $50 million in Annual Recurring Revenue and serving 60,000+ customers with more than 5 million supplement servings. The company's NSF Certified for Sport® Daily Ultimate Essentials product has been part of Sabalenka's daily routine since early 2025, contributing to her successful season including titles in Brisbane, Miami, and Madrid.

Prenetics (NASDAQ: PRE) has become the first healthcare company to implement a major Bitcoin treasury strategy, purchasing 187.42 BTC worth $20 million at an average price of $106,712 per Bitcoin. The company appointed Andy Cheung, former COO of OKEx, to its Board of Directors to oversee this initiative. With a strengthened balance sheet of $117M and zero debt, Prenetics plans to allocate the majority of its assets to Bitcoin. The company's core business is performing well, with projected 2025 revenue of $80-100M and profitability expected in Q4 2025. Their IM8 Health platform is showing strong growth with $50M+ ARR and 55,000 customers. The strategy includes institutional partnerships, alpha-generating approaches, and operational Bitcoin integration across their consumer platforms. The company is supported by crypto industry leaders including Tracy Hoyos Lopez and Raphael Strauch, founder of TOKEN2049.

Prenetics Global Limited (NASDAQ: PRE) has announced the divestment of ACT Genomics to Delta Electronics in a transaction valued at up to US$71.78 million. Prenetics will receive approximately US$46 million in gross proceeds, boosting its pro-forma cash reserves to US$86 million and short-term assets to US$117 million. The company maintains a debt-free balance sheet and raised its FY2025 revenue outlook to US$80-100 million from US$73-85 million. Following the divestment, Prenetics will focus on three consumer health brands: IM8 (premium supplements), CircleDNA (DNA testing), and Europa (sports nutrition). The company's Q1 2025 revenue reached $14.4 million, a 336.5% YoY increase. IM8, launched just six months ago, has acquired over 55,000 customers with a 91% subscription rate and presence in 31 countries. Additionally, Prenetics holds a 35% stake in Insighta valued at $70 million.

Prenetics reported strong Q1 2025 financial results with revenue from continuing operations reaching $17.3M, up 169.9% YoY. Consumer business revenue (excluding ACT Genomics) grew 336.5% to $14.4M. The company raised its FY2025 revenue outlook to $80-100M from previous $73-85M. IM8, their flagship product, contributed $5.7M in Q1 with 55,000+ customers and 4.9M servings delivered across 31 countries. Q2 IM8 revenue is projected at $8.5M, a 50% QoQ increase. The company maintains a strong financial position with $78M in cash and short-term assets, remaining debt-free. Prenetics announced plans to implement a crypto strategy and Bitcoin adoption as part of their treasury management approach. The company expects to conclude its strategic review of ACT Genomics soon.

IM8, the premium supplement brand co-founded by David Beckham, hosted 'IM8 Vibrante' at Miami Beach's Faena Theater on April 09, 2025. The event gathered approximately 150 wellness influencers, creators, and medical advisors to showcase the brand's approach to science-backed wellness solutions.

Key highlights included:

• Presentations from Scientific Advisory Board members including Dr. Amy Shah, Dr. James DiNicolantonio, and Dr. Jeremy London on longevity science
• Dr. Jim Green's update on IM8's space aging experiment with SpaceX and Oxford University, with a new phase launching April 21, 2025
• Showcase of IM8's flagship product 'Daily Ultimate Essentials'

The event featured discussions on wellness innovation, scientific advancement, and making elite health accessible to all, while strengthening IM8's community of health and wellness advocates.

Prenetics' IM8 Health has expanded its Scientific Advisory Board (SAB) with the addition of two distinguished members: Dr. Jeremy London, a board-certified cardiothoracic surgeon with 25+ years of experience, and Dr. Amy Shah, a double board-certified expert in Internal Medicine. They join an existing prestigious team from institutions including Mayo Clinic, NASA, Cedars-Sinai, and Yale University.

The expanded SAB supports IM8's flagship product, Daily Ultimate Essentials, a clinically-validated all-in-one daily powder supplement designed to replace up to 16 supplements. The product focuses on energy, immunity, digestion, and longevity, featuring NSF certification for Sport.

This strategic expansion occurs as the global supplements market, currently valued at $152 billion, is projected to reach $300 billion by 2028, driven by increasing demand for scientifically-backed products.

Prenetics Global (NASDAQ: PRE), a leading consumer health sciences company, has announced its participation in the 37th Annual ROTH Conference. The event will take place from March 16th to March 18th, 2025, at the Laguna Cliffs Marriott Resort in Dana Point, CA.

CEO Danny Yeung and President of Americas David Vanderveen will be available for one-on-one meetings with investors. Additionally, management will join a panel discussion focused on Longevity and Supplementation on Monday, March 17th at 12:00pm PT. The panel discussion will be accessible via webcast and will be available on Prenetics' investor relations website.

Prenetics (NASDAQ: PRE) reported strong Q4 and full year 2024 results, with Q4 revenue growing 93.5% to $10.5 million and full-year revenue increasing 40.9% to $30.6 million. The company maintains a solid financial position with $84.8 million in cash and short-term assets.

Key highlights include:

• Gross profit from continuing operations reached $4.6 million in Q4 2024 (up 73.1%) and $16.1 million for full-year 2024 (up 82.6%)
• Full-year gross margin improved to 52.6% from 40.6% in 2023
• IM8 Health launch showed promising results with $106 average order value and 83% subscription rate

For 2025, Prenetics projects revenue of $73-85 million, representing 350-450% year-over-year growth. The company expects to achieve profitability by Q4 2025, focusing on consumer health brands IM8, Europa, and CircleDNA.

Prenetics Global (NASDAQ: PRE) has announced a strategic partnership with Humanity Protocol to integrate its CircleDNA service for blockchain-based identity verification. The collaboration aims to provide secure Proof of Personhood credentials using DNA testing and zero-knowledge proof technology.

The company has established a Crypto Strategic Reserve with initial investments of $1.5M distributed across $H tokens ($1M), Bitcoin ($250K), and Solana ($250K). These investments will be reviewed quarterly. Prenetics reported $84.87M in cash and short-term assets as of December 31, 2024.

Additionally, through its joint venture Insighta, Prenetics is advancing in decentralized science (DeSci) with AI-driven early cancer detection, supported by a $30M investment from Tencent. The company's consumer health brand, IM8, is also contributing to DeSci initiatives by applying scientific advancements to daily health and longevity solutions.